Review
Immunology
Abolfazl Maghrouni, Maryam Givari, Mohammad Jalili-Nik, Hamid Mollazadeh, Bahram Bibak, Mohammad Montazami Sadeghi, Amir R. Afshari, Thomas P. Johnston, Amirhossein Sahebkar
Summary: GBM, an immunosuppressive brain tumor, remains difficult to manage despite current treatments. Immunotherapy, particularly checkpoint inhibitors, has potential for GBM treatment but faces challenges due to the tumor's immunosuppressive microenvironment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Taisuke Kaiho, Hidemi Suzuki, Atsushi Hata, Hiroki Matsumoto, Kazuhisa Tanaka, Yuichi Sakairi, Shinichiro Motohashi, Ichiro Yoshino
Summary: Immune checkpoint molecules, such as PD-1 and PD-L1, have been shown to be important in lung cancer treatment. This study explored the role of these proteins in acute rejection in a mouse model of tracheal transplantation and found that PD-L1 Fc recombinant protein could decrease inflammatory cytokines and reduce the proportion of CD4+ T cells, suggesting a potential novel target for immunotherapy in lung transplantation.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Chunyi Shen, Zhen Zhang, Yonggui Tian, Feng Li, Lingxiao Zhou, Wenyi Jiang, Li Yang, Bin Zhang, Liping Wang, Yi Zhang
Summary: The study demonstrated that combining SFN with CAR-T cells enhanced cytotoxicity and antitumor functions by modulating the PD-1/PD-L1 pathway, suggesting a promising strategy for cancer immunotherapy.
Article
Biochemistry & Molecular Biology
Nadia Mensali, Pierre Dillard, Artem Fayzullin, Hakan Koksal, Gustav Gaudernack, Gunnar Kvalheim, Else Marit Inderberg, Sebastien Walchli
Summary: The success of adoptive cell therapy relies on the ability of immune cells to persist and function optimally in the tumor microenvironment. Novel genetic strategies to manipulate the PD1/PD-L1 axis can improve antitumor immunity and reveal new targets through PD-L1 positivity.
Review
Oncology
Xingcheng Yang, Ling Ma, Xiaoying Zhang, Liang Huang, Jia Wei
Summary: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases that arise from the bone marrow. Dysregulated immune microenvironment, including the molecules PD-1 and PD-L1, play important roles in the pathogenesis of MDS and AML. However, clinical trials using PD-1/PD-L1 inhibitors have reported mixed responses in patients with these diseases.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Review
Oncology
David Johnson, Brigette B. Y. Ma
Summary: The upregulation of the PD-1/PD-L1 pathway is a possible immune-evasion mechanism in Epstein-Barr virus-associated nasopharyngeal cancer (NPC). Therapeutic targeting of this pathway is actively researched in NPC, with multiple monoclonal antibodies currently under evaluation in clinical settings. Combinatorial strategies involving cytotoxic chemotherapy, radiotherapy, and other immunotherapeutic agents are also being explored in clinical trials for NPC.
Review
Immunology
Huizhen Cao, Tianyu Wu, Xue Zhou, Shuyang Xie, Hongfang Sun, Yunxiao Sun, Youjie Li
Summary: Leukemia cells induce immunosuppression of the bone marrow microenvironment, preventing the immune system from clearing tumor cells. The PD-1/PD-L1 axis acts as a significant mechanism for tumor cells to evade immune surveillance. The development of drugs targeting PD-1/PD-L1 in leukemia is still at the clinical-trial stage.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Paolo Andrea Zucali, Chia-Chi Lin, Bradley C. Carthon, Todd M. Bauer, Marcello Tucci, Antoine Italiano, Roberto Iacovelli, Wu-Chou Su, Christophe Massard, Mansoor Saleh, Gennaro Daniele, Alastair Greystoke, Martin Gutierrez, Shubham Pant, Ying-Chun Shen, Matteo Perrino, Robin Meng, Giovanni Abbadessa, Helen Lee, Yingwen Dong, Marielle Chiron, Rui Wang, Laure Loumagne, Lucie Lepine, Johann de Bono
Summary: The study investigated the safety, tolerability, and efficacy of a combination treatment with anti-CD38 and anti-PD-1 antibodies in patients with mCRPC and NSCLC. The results showed manageable safety profile, reduction in CD38+ immune cells in the tumor microenvironment, and activation of peripheral T cells, but no significant antitumor activity was observed in this small cohort of patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Zana Karami, Keywan Mortezaee, Jamal Majidpoor
Summary: To overcome resistance and relapse in immune checkpoint inhibitor therapy, researchers have developed bispecific inhibitors that can simultaneously target transforming growth factor-beta (TGF-β) signaling and PD-1/PD-L1 pathways. These inhibitors reinvigorate immune response, inhibit regulatory T cells, and increase the density of anti-tumor macrophages, leading to reduced relapse rates and durable anticancer therapy. The bispecific approach is particularly effective in HPV-positive patients and those with high PD-L1 expression or immune-excluded phenotype. It can also be safely combined with other therapies like vaccination, radiation, and chemotherapy.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Andrzej Kowalski, Katarzyna Malinowska, Jurek Olszewski, Hanna Zielinska-Blizniewska
Summary: The interaction of PD-1 and PD-L1 in laryngeal tumors allows cancer cells to escape from the immune system. Gene expression of PD-1 and PD-L1 was significantly higher in tumor tissue compared to unchanged mucosa, with higher expression levels associated with larger tumor sizes. These findings suggest potential for targeted immunotherapy with anti-PD1 and anti-PD-L1 monoclonal antibodies in treating laryngeal tumors.
Review
Oncology
Chao Cheng, Lingdun Zhuge, Xin Xiao, Siyuan Luan, Yong Yuan
Summary: As the predominant treatment option for advanced esophageal cancer, PD-1 and PD-L1 inhibitors provide new hope to clinical practice. However, some patients do not respond to this therapy and most initially sensitive patients eventually develop resistance. Therefore, it is critical to understand the mechanisms of resistance and explore efficient strategies to overcome it, in order to expand the benefit of immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Chia-Jung Li, Li-Te Lin, Ming-Feng Hou, Pei-Yi Chu
Summary: Significant progress has been made in understanding the role of PD-L1 in breast cancer, especially in TNBC. Early clinical trials of PD-L1/PD-1 inhibitors have shown efficacy in refractory metastatic breast cancer patients, particularly in TNBC. Mechanisms and factors influencing the immunoediting process have been summarized and analyzed in detail.
Review
Immunology
Yuedi Zhang, Qiulin Cui, Manman Xu, Duo Liu, Shuzhong Yao, Ming Chen
Summary: Immunotherapies have revolutionized cancer treatment, but recurrent ovarian cancer remains difficult to treat. Recurrent ovarian cancer is a cold tumor with limited response to immunotherapy. However, combining immunotherapy with other treatments may improve outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Lin Zhang, Bo Hao, Zhihua Geng, Qing Geng
Summary: Toripalimab, a selective anti-PD-1 monoclonal antibody, has shown anti-tumor effects in melanoma, nasopharyngeal carcinoma, and urothelial carcinoma, and could be a valuable choice for future tumor treatment decision-making.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Rilan Bai, Jiuwei Cui
Summary: Antibodies targeting PD-1/PD-L1 have been considered breakthrough therapies for cancer. In addition to T cell-driven immune responses, blocking PD-1/PD-L1 may also enhance the function and activity of NK cells, which are often overlooked in previous studies.
FRONTIERS IN IMMUNOLOGY
(2022)
